1,535 results on '"Saab, Sammy"'
Search Results
2. The Impact of Renal Function on Hepatic Encephalopathy Following TIPS Placement for Refractory Ascites.
- Author
-
Zhao, Matthew, Saab, Sammy, Craw, Chloe, and Lee, Edward
- Subjects
CKD ,HE ,TIPS ,chronic kidney disease ,hemodialysis ,hepatic encephalopathy ,transjugular intrahepatic portosystemic shunt - Abstract
BACKGROUND: The impact of renal function on hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunt (TIPS) placement for refractory ascites is poorly understood. We investigated the role of renal function on HE following TIPS placement. METHODS: A retrospective study was performed for patients undergoing TIPS for refractory ascites from 2007-2019. Patients were stratified by GFR at time of TIPS placement and by whether they were on hemodialysis (HD). Chronic kidney disease (CKD) stage 3 or higher was defined as pre-TIPS GFR < 60 for at least 3 months. Logistic regression analyses were used to identify the role of GFR and CKD at time of TIPS placement on HE within 60 days post TIPS placement. RESULTS: Among 201 TIPS patients for refractory ascites (61% male; mean age 59.1), 78 (39%) patients were in CKD, and 16 (21%) were on HD. Mean GFR at time of TIPS placement was 62.7 ± 28.2 for all non-HD patients (n = 185). Compared with the GFR ≥ 90 group, GFR < 30 or HD (OR, 3.56; 95%CI, 1.19-10.7; p = 0.023) and CKD (OR, 2.52; 95%CI, 1.40-4.53; p = 0.002) at time of TIPS placement were significant predictors of post-TIPS placement HE within 60 days. GFRs between 30-60 and 60-90 were not significant predictors. CONCLUSIONS: In TIPS patients for recurrent ascites, patients with acutely impaired renal function or chronic renal dysfunction were at an increased risk for HE after TIPS.
- Published
- 2023
3. Author Correction: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer
- Author
-
Stackpole, Mary L., Zeng, Weihua, Li, Shuo, Liu, Chun-Chi, Zhou, Yonggang, He, Shanshan, Yeh, Angela, Wang, Ziye, Sun, Fengzhu, Li, Qingjiao, Yuan, Zuyang, Yildirim, Asli, Chen, Pin-Jung, Winograd, Paul, Tran, Benjamin, Lee, Yi-Te, Li, Paul Shize, Noor, Zorawar, Yokomizo, Megumi, Ahuja, Preeti, Zhu, Yazhen, Tseng, Hsian-Rong, Tomlinson, James S., Garon, Edward, French, Samuel, Magyar, Clara E., Dry, Sarah, Lajonchere, Clara, Geschwind, Daniel, Choi, Gina, Saab, Sammy, Alber, Frank, Wong, Wing Hung, Dubinett, Steven M., Aberle, Denise R., Agopian, Vatche, Han, Steven-Huy B., Ni, Xiaohui, Li, Wenyuan, and Zhou, Xianghong Jasmine
- Published
- 2024
- Full Text
- View/download PDF
4. DDS Profile: Sammy Saab, MD, MPH
- Author
-
Saab, Sammy
- Published
- 2024
- Full Text
- View/download PDF
5. HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma
- Author
-
Sun, Na, Zhang, Ceng, Lee, Yi‐Te, Tran, Benjamin V, Wang, Jing, Kim, Hyoyong, Lee, Junseok, Zhang, Ryan Y, Wang, Jasmine J, Hu, Junhui, Zhang, Zhicheng, Alsudaney, Manaf S, Hou, Kuan‐Chu, Tang, Hubert, Zhang, Tiffany X, Liang, Icy Y, Zhou, Ziang, Chen, Mengxiang, Yeh, Angela Hsiao‐Jiun, Li, Wenyuan, Zhou, Xianghong Jasmine, Chang, Helena R, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Noureddin, Mazen, Ayoub, Walid S, Kuo, Alexander, Sundaram, Vinay, Al‐Ghaieb, Buraq, Palomique, Juvelyn, Kosari, Kambiz, Kim, Irene K, Todo, Tsuyoshi, Nissen, Nicholas N, Tomasi, Maria Lauda, You, Sungyong, Posadas, Edwin M, Wu, James X, Wadehra, Madhuri, Sim, Myung‐Shin, Li, Yunfeng, Wang, Hanlin L, French, Samuel W, Lu, Shelly C, Wu, Lily, Pei, Renjun, Liang, Li, Yang, Ju Dong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Liver Cancer ,Prevention ,Liver Disease ,Cancer ,Clinical Research ,Digestive Diseases ,Rare Diseases ,4.2 Evaluation of markers and technologies ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Humans ,Carcinoma ,Hepatocellular ,Liver Neoplasms ,Biomarkers ,Tumor ,Extracellular Vesicles ,Membrane Proteins ,Electrocardiography ,Glypicans ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Immunology ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background and aimsThe sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay for early detection of HCC.Approach and resultsTissue microarray was used to evaluate four potential HCC-associated protein markers. An HCC EV surface protein assay, composed of covalent chemistry-mediated HCC EV purification and real-time immuno-polymerase chain reaction readouts, was developed and optimized for quantifying subpopulations of EVs. An HCC EV ECG score, calculated from the readouts of three HCC EV subpopulations ( E pCAM + CD63 + , C D147 + CD63 + , and G PC3 + CD63 + HCC EVs), was established for detecting early-stage HCC. A phase 2 biomarker study was conducted to evaluate the performance of ECG score in a training cohort ( n = 106) and an independent validation cohort ( n = 72).Overall, 99.7% of tissue microarray stained positive for at least one of the four HCC-associated protein markers (EpCAM, CD147, GPC3, and ASGPR1) that were subsequently validated in HCC EVs. In the training cohort, HCC EV ECG score demonstrated an area under the receiver operating curve (AUROC) of 0.95 (95% confidence interval [CI], 0.90-0.99) for distinguishing early-stage HCC from cirrhosis with a sensitivity of 91% and a specificity of 90%. The AUROCs of the HCC EV ECG score remained excellent in the validation cohort (0.93; 95% CI, 0.87-0.99) and in the subgroups by etiology (viral: 0.95; 95% CI, 0.90-1.00; nonviral: 0.94; 95% CI, 0.88-0.99).ConclusionHCC EV ECG score demonstrated great potential for detecting early-stage HCC. It could augment current surveillance methods and improve patients' outcomes.
- Published
- 2023
6. Role of Biomarkers to Assess the Use of Alcohol
- Author
-
Shetty, Akshay, De La Torre, Sergio, Ibrahim, Brittney, Hong, Andrew, Meza, Julio, and Saab, Sammy
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Chronic Liver Disease and Cirrhosis ,Substance Misuse ,Alcoholism ,Alcohol Use and Health ,Digestive Diseases ,Liver Disease ,Transplantation ,Organ Transplantation ,Oral and gastrointestinal ,Stroke ,Good Health and Well Being ,Humans ,Ethanol ,Liver Diseases ,Alcoholic ,Liver Transplantation ,Alcohol Drinking ,Biomarkers ,alcohol biomarkers ,PEth ,phosphatidylethanol ,ethyl glucuronide ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Alcohol-associated liver disease has seen a significant rise in the last 2 decades, with an associated rise in the need for accurate alcohol use assessment. Alcohol use has been associated with poor outcomes in both the pre-liver transplant and post-liver transplant patients. Patients with alcohol use disorder often under-report their alcohol consumption because of varying factors, highlighting the need for objective assessment of alcohol use. Aside from the available self-report questionnaires, multiple serologic biomarkers are currently available to assist clinicians to assess recent alcohol consumption among patients with chronic liver disease, liver transplant candidates, and recipients. In this review, we will assess some of these alcohol biomarkers, discuss their strengths and weakness, and review-available data to discuss their role in pre-liver transplant and post-liver transplant population.
- Published
- 2023
7. Clinical Impact and Safety of Non-Target Punctures (NTP) during Portal Vein Access in TIPS Procedure
- Author
-
Feinggumloon, Sasikorn, Haber, Zachary, Saab, Sammy, Kaldas, Fady, Eghbalieh, Navid, Luong, Thanh T, McWilliams, Justin P, and Lee, Edward Wolfgang
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Prevention ,Patient Safety ,Liver Disease ,Good Health and Well Being ,transjugular intrahepatic portosystemic shunt ,complications ,non-target puncture ,cirrhosis ,portal vein access ,angiography ,portal vein ,portal hypertension ,variceal bleeding ,refractory ascites ,Biochemistry and cell biology ,Pharmacology and pharmaceutical sciences ,Medicinal and biomolecular chemistry - Abstract
BackgroundAlthough non-target puncture (NPT)-related complications are well known to clinicians performing TIPS, there is no NTP-focused study to assess the true clinical sequalae of NTP-related complications. In this study, the aim was to evaluate the incidence, safety, clinical outcomes and complications related to NTPs during the portal access of TIPS procedures.MethodsA retrospective review of 369 TIPS procedures from October 2007 to September 2019 was performed. We identified inadvertent NTPs, including biliary, hepatic artery, lymphatic and capsular punctures. Next, the medical records and images were reviewed and analyzed to assess the safety and clinical outcomes of these cohorts.ResultsA total of 71 NTPs were identified in 56 patients (15.18% of 369 patients). Of 369 TIPS patients, there were (1) 28 biliary punctures (7.6%), (2) 16 extracapsular punctures (4.3%), (3) 15 lymphatic punctures (4.1%) and (4) 12 hepatic artery punctures (3.3%). The overall complication rate was 2.2% (8/369). Based on the Clavien-Dindo classification, three patients (0.8%) had a minor complication. In addition, five patients (1.4%) experienced grade II-V major complications, such as symptomatic hemoperitoneum, arterio-biliary fistula or hemorrhagic shock leading to death. Mortality (0.5%) was only caused by extracapsular puncture combined with other NTP.ConclusionsNTPs during the portal access of TIPS procedures are associated with low complication risk. However, when extracapsular punctures are combined with other NTPs, a more severe complication, including mortality, can occur. Nevertheless, all patients with NTP should be closely monitored at a higher level of care after TIPS placement.
- Published
- 2023
8. Impact of solid organ transplant status on outcomes of hospitalized patients with COVID-19 infection.
- Author
-
Schaenman, Joanna, Byford, Hannah, Grogan, Tristan, Motwani, Yash, Beaird, Omer E, Kamath, Megan, Lum, Erik, Meneses, Katherine, Sayah, David, Vucicevic, Darko, and Saab, Sammy
- Subjects
Humans ,Organ Transplantation ,Pandemics ,Transplant Recipients ,COVID-19 ,Immunosuppression Therapy ,comorbidities ,solid organ transplant ,Transplantation ,Clinical Research ,Patient Safety ,Good Health and Well Being ,Clinical Sciences ,Surgery - Abstract
BackgroundThe COVID-19 pandemic has caused significant morbidity and mortality in solid organ transplant (SOT) recipients. However, it remains unclear whether the risk factor for SOT patients is the immunosuppression inherent to transplantation versus patient comorbidities.MethodsWe reviewed outcomes in a cohort of SOT (n = 129) and non-SOT (NSOT) patients (n = 708) admitted to the University of California, Los Angeles for COVID-19 infection. Data analyses utilized multivariate logistic regression to evaluate the impact of patient demographics, comorbidities, and transplant status on outcomes. SOT patients were analyzed by kidney SOT (KSOT) versus nonkidney SOT (NKSOT) groups.ResultsSOT and NSOT patients with COVID-19 infection differed in terms of patient age, ethnicity, and comorbidities. NKSOT patients were the most likely to experience death, with a mortality rate of 16.2% compared with 1.8% for KSOT and 8.3% for NSOT patients (p = .013). Multivariable analysis of hospitalized patients revealed that patient age (odds ratio [OR] 2.79, p = .001) and neurologic condition (OR 2.66, p
- Published
- 2022
9. DDS Perspective: Etiquette in Medicine
- Author
-
Saab, Sammy
- Published
- 2024
- Full Text
- View/download PDF
10. Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer
- Author
-
Stackpole, Mary L, Zeng, Weihua, Li, Shuo, Liu, Chun-Chi, Zhou, Yonggang, He, Shanshan, Yeh, Angela, Wang, Ziye, Sun, Fengzhu, Li, Qingjiao, Yuan, Zuyang, Yildirim, Asli, Chen, Pin-Jung, Winograd, Paul, Tran, Benjamin, Lee, Yi-Te, Li, Paul Shize, Noor, Zorawar, Yokomizo, Megumi, Ahuja, Preeti, Zhu, Yazhen, Tseng, Hsian-Rong, Tomlinson, James S, Garon, Edward, French, Samuel, Magyar, Clara E, Dry, Sarah, Lajonchere, Clara, Geschwind, Daniel, Choi, Gina, Saab, Sammy, Alber, Frank, Wong, Wing Hung, Dubinett, Steven M, Aberle, Denise R, Agopian, Vatche, Han, Steven-Huy B, Ni, Xiaohui, Li, Wenyuan, and Zhou, Xianghong Jasmine
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Bioinformatics and Computational Biology ,Genetics ,Oncology and Carcinogenesis ,Digestive Diseases ,Cancer ,Clinical Research ,Colo-Rectal Cancer ,Human Genome ,Lung ,Lung Cancer ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Cell-Free Nucleic Acids ,Cost-Benefit Analysis ,Early Detection of Cancer ,Epigenome ,Humans ,Stomach Neoplasms - Abstract
Early cancer detection by cell-free DNA faces multiple challenges: low fraction of tumor cell-free DNA, molecular heterogeneity of cancer, and sample sizes that are not sufficient to reflect diverse patient populations. Here, we develop a cancer detection approach to address these challenges. It consists of an assay, cfMethyl-Seq, for cost-effective sequencing of the cell-free DNA methylome (with > 12-fold enrichment over whole genome bisulfite sequencing in CpG islands), and a computational method to extract methylation information and diagnose patients. Applying our approach to 408 colon, liver, lung, and stomach cancer patients and controls, at 97.9% specificity we achieve 80.7% and 74.5% sensitivity in detecting all-stage and early-stage cancer, and 89.1% and 85.0% accuracy for locating tissue-of-origin of all-stage and early-stage cancer, respectively. Our approach cost-effectively retains methylome profiles of cancer abnormalities, allowing us to learn new features and expand to other cancer types as training cohorts grow.
- Published
- 2022
11. Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy
- Author
-
Chow, Kenneth W., Ibrahim, Brittney M., Yum, Jung J., Dang, An, Dang, Long, Chen, Kuan-Ting, Jackson, Nicholas J., and Saab, Sammy
- Published
- 2023
- Full Text
- View/download PDF
12. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico
- Author
-
Flores, Yvonne N, Amoon, Aryana T, Su, Baolong, Velazquez-Cruz, Rafael, Ramírez-Palacios, Paula, Salmerón, Jorge, Rivera-Paredez, Berenice, Sinsheimer, Janet S, Lusis, Aldons J, Huertas-Vazquez, Adriana, Saab, Sammy, Glenn, Beth A, May, Folasade P, Williams, Kevin J, Bastani, Roshan, and Bensinger, Steven J
- Subjects
Medical Biochemistry and Metabolomics ,Biomedical and Clinical Sciences ,Digestive Diseases ,Liver Disease ,Nutrition ,Obesity ,Biomedical Imaging ,Women's Health ,Chronic Liver Disease and Cirrhosis ,Clinical Research ,2.1 Biological and endogenous factors ,Oral and gastrointestinal ,Adult ,Aged ,Biomarkers ,Case-Control Studies ,Cholesterol ,Cohort Studies ,Female ,Humans ,Lipidomics ,Lysophosphatidylcholines ,Male ,Mexico ,Middle Aged ,Non-alcoholic Fatty Liver Disease ,ROC Curve ,Sphingomyelins ,Triglycerides ,Triacylglycerol desaturation ,Nonalcoholic fatty liver disease ,NAFLD ,Latinos ,Mexican ,Cross-sectional study ,Other Information and Computing Sciences ,Nutrition and Dietetics ,Nutrition & Dietetics ,Medical biochemistry and metabolomics ,Nutrition and dietetics - Abstract
BackgroundNonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and cirrhosis. NAFLD is mediated by changes in lipid metabolism and known risk factors include obesity, metabolic syndrome, and diabetes. The aim of this study was to better understand differences in the lipid composition of individuals with NAFLD compared to controls, by performing direct infusion lipidomics on serum biospecimens from a cohort study of adults in Mexico.MethodsA nested case-control study was conducted with a sample of 98 NAFLD cases and 100 healthy controls who are participating in an on-going, longitudinal study in Mexico. NAFLD cases were clinically confirmed using elevated liver enzyme tests and liver ultrasound or liver ultrasound elastography, after excluding alcohol abuse, and 100 controls were identified as having at least two consecutive normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (
- Published
- 2021
13. History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites.
- Author
-
Saab, Sammy, Zhao, Matthew, Asokan, Ishan, Yum, Jung Jun, and Lee, Edward Wolfgang
- Subjects
Liver Disease ,Clinical Research ,Digestive Diseases ,Clinical Sciences - Abstract
IntroductionThe outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with hepatic encephalopathy (HE) are controversial. We studied the relationship of pre-TIPS HE in patients undergoing TIPS for refractory ascites on all-cause mortality and development of post-TIPS HE.MethodsA single-center retrospective comparison study was performed for patients undergoing TIPS for refractory ascites. Survival by history of pre-TIPS HE was demonstrated with Kaplan-Meier curves. Univariate and multivariate logistic regression analyses were performed to identify the predictors of post-TIPS clinical outcomes for patients with and without pre-TIPS HE.ResultsWe identified 202 TIPS recipients (61% male, mean ± SD; age 59.1 ± 10.2 years; mean model for end-stage liver disease score 17.3 ± 6.9). Pre-TIPS HE did not predispose patients for increased all-cause mortality, increased risk of experiencing HE within 60 days, or increased risk of hospital admission for HE within 6 months. A multivariate analysis demonstrated that total bilirubin (odds ratio [OR] 1.03; P = 0.016) and blood urea nitrogen (OR 1.15; P = 0.002) were predictors for all-cause mortality within 6 months post-TIPS. Age ≥65 years (OR 3.92; P = 0.004), creatinine (OR 2.22; P = 0.014), and Child-Pugh score (OR 1.53; P = 0.006) were predictors for HE within 60 days post-TIPS. Predictors of intensive care admission for HE within 6 months post-TIPS included age ≥65 years (OR 8.84; P = 0.018), history of any admission for HE within 6 months pre-TIPS (OR 8.42; P = 0.017), and creatinine (OR 2.22; P = 0.015).DiscussionIf controlled, pre-TIPS HE does not adversely impact patient survival or clinical outcomes, such as development of HE within 60 days of TIPS or hospital admission for HE within 6 months. Patients may be able to undergo TIPS for refractory ascites despite a history of HE.
- Published
- 2021
14. Accuracy and Safety of 1,055 Transjugular Liver Biopsies in Postliver Transplant Patients.
- Author
-
Lee, Edward Wolfgang, Sue, Megan J, Saab, Sammy, DiNorcia, Joseph, McWilliams, Justin P, Kaldas, Fady, Ding, Peng-Xu, Padia, Siddharth A, Agopian, Vatche, Farmer, Douglas, and Busuttil, Ronald W
- Subjects
Clinical Sciences - Abstract
IntroductionThe purpose of this study was to investigate the rates of complications and diagnostic yield of transjugular liver biopsy (TJLB) in deceased donor liver transplant (DDLT) recipients.MethodsFrom January 2009 to December 2019, 1,055 TJLBs were performed in 603 adult DDLT recipients with a mean age of 54 (±12 years). Data were retrospectively reviewed to determine the diagnostic efficacy and incidence of major and minor complications in the 3-day and 1-month period after TJLB. In addition, data were stratified according to platelet count and international normalized ratio to determine the safety of TJLB in patients with varying degrees of coagulopathy.ResultsTJLB yielded diagnostic rate of 98.1% (1,035/1,055), with an overall complication rate of 8.3% (88/1,055). Major complications accounted for 0.85% (9/1,055), and minor complications occurred in 7.48% (79/1,055). When patients were stratified by platelet count (0-50, 51-100, 101-200, 201-300, and >300 × 103 platelets/μL), no significant difference was noted in complication rates (9.5%, 8.6%, 7.6%, 8.5%, and 10.7%, respectively). When grouped by international normalized ratio (0-1, 1.1-2.0, 2.1-3.0, and >3.0), there was no statistical difference in complication rates (8.3%, 8.5%, 7.7%, and 0%, respectively).DiscussionTJLB is a safe, adequate, and effective method to investigate hepatic disorders in DDLT recipients with severe coagulopathy.
- Published
- 2021
15. Covalent Chemistry‐Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma
- Author
-
Sun, Na, Lee, Yi‐Te, Kim, Minhyung, Wang, Jasmine J, Zhang, Ceng, Teng, Pai‐Chi, Qi, Dongping, Zhang, Ryan Y, Tran, Benjamin V, Lee, Yue Tung, Ye, Jinglei, Palomique, Juvelyn, Nissen, Nicholas N, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Posadas, Edwin M, Liang, Li, Pei, Renjun, Yang, Ju Dong, You, Sungyong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen
- Subjects
Digestive Diseases ,Genetics ,Prevention ,Rare Diseases ,Liver Disease ,Biotechnology ,Cancer ,Clinical Research ,Liver Cancer ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,circulating tumor cells ,click chemistry ,hepatocellular carcinoma ,nanosubstrate ,transcriptome profiling - Abstract
Transcriptomic profiling of tumor tissues introduces a large database, which has led to improvements in the ability of cancer diagnosis, treatment, and prevention. However, performing tumor transcriptomic profiling in the clinical setting is very challenging since the procurement of tumor tissues is inherently limited by invasive sampling procedures. Here, we demonstrated the feasibility of purifying hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from clinical patient samples with improved molecular integrity using Click Chips in conjunction with a multimarker antibody cocktail. The purified CTCs were then subjected to mRNA profiling by NanoString nCounter platform, targeting 64 HCC-specific genes, which were generated from an integrated data analysis framework with 8 tissue-based prognostic gene signatures from 7 publicly available HCC transcriptomic studies. After bioinformatics analysis and comparison, the HCC CTC-derived gene signatures showed high concordance with HCC tissue-derived gene signatures from TCGA database, suggesting that HCC CTCs purified by Click Chips could enable the translation of HCC tissue molecular profiling into a noninvasive setting.
- Published
- 2021
16. Orthotopic Heart and Combined Heart Liver Transplantation: the Ultimate Treatment Option for Failing Fontan Physiology
- Author
-
Reardon, Leigh C, Lin, Jeannette P, VanArsdell, Glen S, Kaldas, Fady M, Lluri, Gentian, Tan, Weiyi, Whalen, Katrina M, Cruz, Daniel, Nsair, Ali, Deng, Mario C, Moore, Melissa A, Laks, Hillel, Biniwale, Reshma M, Saab, Sammy, Baird, Andrew, Wilson, James M, Lubin, Lorraine N, Marijic, Jure, Williams, Tiffany M, Wray, Christopher L, Meltzer, Joseph S, Gudzenko, Vadim, Kratzert, Wolf B, Neelankavil, Jacques, Venick, Robert S, and Aboulhosn, Jamil A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Organ Transplantation ,Congenital Structural Anomalies ,Pediatric ,Cardiovascular ,Biomedical Imaging ,Perinatal Period - Conditions Originating in Perinatal Period ,Liver Disease ,Transplantation ,Digestive Diseases ,Heart Disease ,Evaluation of treatments and therapeutic interventions ,6.4 Surgery ,Fontan ,Single ventricle ,Liver transplant ,Heart transplant ,Enteropathy ,Embolization - Abstract
Purpose of the reviewThis is a comprehensive update on failing Fontan physiology and the role of heart and combined heart and liver transplantation in the current era.Recent findingsSingle ventricle physiology encompasses a series of rare congenital cardiac abnormalities that are characterized by absence of or hypoplasia of one ventricle. This effectively results in a single ventricular pumping chamber. These abnormalities are rarely compatible with long-term survival if left without surgical palliation in the first few years of life. Surgical treatment of single ventricle physiology has evolved over the past 60 years and is characterized by numerous creative innovations. These include the development of arteriopulmonary shunts, the evolution of partial cavopulmonary connections, and the eventual development of the "Fontan" operation. Regardless of the type of Fontan modification, the long-term consequences of the Fontan operation are predominantly related to chronic central venous hypertension and the multi-organ consequences thereof. Atrial arrhythmias can further compromise this circulation.Patients with single ventricle physiology represent a special sub-segment of congenital cardiac transplants and are arguably the most challenging patients considered for transplantation.SummaryThis review describes in detail the challenges and opportunities of heart and liver transplantation in Fontan patients, as viewed and managed by the experienced team at the Ahmanson/UCLA Adult Congenital Heart Center.
- Published
- 2021
17. Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease
- Author
-
Chow, Kenneth W., Futela, Pragyat, Saharan, Aryan, and Saab, Sammy
- Published
- 2023
- Full Text
- View/download PDF
18. Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients
- Author
-
Saab, Sammy, Pham, Nguyen, Wu, William, Dang, Long, Dang, An, Yum, Jung, Shim, Kisub, and Wu, Steven
- Published
- 2022
- Full Text
- View/download PDF
19. Anticoagulation for the Treatment of Portal Vein Thrombosis in Cirrhosis: A Systematic Review and Meta-Analysis of Comparative Studies
- Author
-
Yao, Calvin, Zhao, Matthew, Ibrahim, Brittney, and Saab, Sammy
- Published
- 2023
- Full Text
- View/download PDF
20. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.
- Author
-
Sun, Na, Lee, Yi-Te, Zhang, Ryan Y, Kao, Rueihung, Teng, Pai-Chi, Yang, Yingying, Yang, Peng, Wang, Jasmine J, Smalley, Matthew, Chen, Pin-Jung, Kim, Minhyung, Chou, Shih-Jie, Bao, Lirong, Wang, Jing, Zhang, Xinyue, Qi, Dongping, Palomique, Juvelyn, Nissen, Nicolas, Han, Steven-Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Markovic, Daniela, Elashoff, David, Yu, Hsiao-Hua, Li, Huiying, Heaney, Anthony P, Posadas, Edwin, You, Sungyong, Yang, Ju Dong, Pei, Renjun, Agopian, Vatche G, Tseng, Hsian-Rong, and Zhu, Yazhen
- Subjects
Humans ,Carcinoma ,Hepatocellular ,Liver Neoplasms ,Liver Cirrhosis ,Disease Progression ,Dimethylpolysiloxanes ,RNA ,Messenger ,Diagnosis ,Differential ,Neoplasm Staging ,Microfluidic Analytical Techniques ,Case-Control Studies ,ROC Curve ,Reverse Transcriptase Polymerase Chain Reaction ,Nanostructures ,Computer Simulation ,Aged ,Middle Aged ,Female ,Male ,Nanowires ,Early Detection of Cancer ,Lab-On-A-Chip Devices ,Hep G2 Cells ,Click Chemistry ,Extracellular Vesicles ,Biomarkers ,Tumor ,Liquid Biopsy ,Computational Chemistry - Abstract
We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).
- Published
- 2020
21. Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance
- Author
-
Kimble, Mabel Michille, Javanbakht, Marjan, Chew, Kara W, Stafylis, Chrysovalantis, He, Di, Ramirez, Samantha, Baik, Yeonsoo, Saab, Sammy, and Klausner, Jeffrey D
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Hepatitis ,Chronic Liver Disease and Cirrhosis ,Aging ,Prevention ,Hepatitis - C ,Clinical Research ,Infectious Diseases ,Health Services ,Liver Disease ,Emerging Infectious Diseases ,Digestive Diseases ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Black or African American ,Aged ,California ,Female ,Hepacivirus ,Hepatitis C ,Hepatitis C Antibodies ,Humans ,Male ,Middle Aged ,RNA ,Viral ,Remission ,Spontaneous ,Renal Insufficiency ,Chronic ,Retrospective Studies ,White People ,Young Adult ,Epidemiology ,Spontaneous clearance ,Microbiology ,Clinical Sciences ,Medical Microbiology ,Clinical sciences ,Medical microbiology ,Public health - Abstract
BackgroundIn the United States Hepatitis C virus (HCV) viral clearance is estimated to range between 20 and 30%. The objective of this study was to estimate the frequency of HCV clearance and identify correlates of viral clearance among patients newly identified as HCV antibody positive in a large urban health system in Los Angeles, California.MethodsWe identified patients between November 2015 and September 2017 as part of a newly implemented HCV screening and linkage-to-care program at University of California Los Angeles (UCLA) Health System. All patients were eligible for screening, though there were additional efforts to screen patients born between 1945 and 1965. We reviewed Medical records to categorize anti-HCV antibody positive patients as having spontaneously cleared HCV infection (HCV RNA not detected) or not (HCV RNA detected). We excluded those with a prior history of anti-HCV positivity or history of HCV treatment. We compared differences between those with and without detectable HCV RNA using chi-square test, Fisher's exact test, and t-test as appropriate. We assessed factors associated with HCV clearance using logistic regression analysis.ResultsAmong the 320 patients included in this study, 56% were male. Baby boomers (52-72 years of age) comprised the single largest age group (62%). We found spontaneous HCV clearance in 58% (n = 185). HCV viral clearance was slightly higher among women as compared to men (63% vs. 53%; p value = 0.07) and varied by race/ethnicity: clearance among Blacks/African Americans was 37% vs. 58% among whites (p value = 0.02). After adjusting for age, race/ethnicity, and sex we found that those diagnosed with chronic kidney disease had a tendency of decreased HCV viral clearance (adjusted OR = 0.34; 95% CI 0.14-1.03).ConclusionOf those patients newly identified as anti-HCV positive, 58% had cleared HCV virus, while the rest showed evidence of active infection. In addition, we found that clearance varied by race/ethnicity and clinical characteristics.
- Published
- 2019
22. Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature
- Author
-
Chow, Kenneth W., Pham, Nguyen V., Ibrahim, Britney M., Hong, Kimberly, and Saab, Sammy
- Published
- 2022
- Full Text
- View/download PDF
23. The Evolution of Redo Liver Transplantation Over 35 years: Analysis of 654 Consecutive Adult Liver Retransplants at a Single Center
- Author
-
Kaldas, Fady M., Horwitz, Julian K., Noguchi, Daisuke, Korayem, Islam M., Markovic, Daniela, Ebaid, Samer, Agopian, Vatche G., Yersiz, Hasan, Saab, Sammy, Han, Steven B., El Kabany, Mohamad M., Choi, Gina, Shetty, Akshay, Singh, Jasleen, Wray, Christopher, Barjaktarvic, Igor, Farmer, Douglas G., and Busuttil, Ronald W.
- Published
- 2023
- Full Text
- View/download PDF
24. Hepatic Encephalopathy
- Author
-
Saab, Sammy, primary
- Published
- 2024
- Full Text
- View/download PDF
25. Cost effectiveness of hepatitis C direct acting agents
- Author
-
Shetty, Akshay, primary, Lee, Michelle, additional, Valenzuela, Julia, additional, and Saab, Sammy, additional
- Published
- 2024
- Full Text
- View/download PDF
26. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door
- Author
-
Frenette, Catherine T., Levy, Cynthia, and Saab, Sammy
- Published
- 2022
- Full Text
- View/download PDF
27. Transjugular Liver Biopsy: Safe Even in Patients With Severe Coagulopathies and Multiple Biopsies.
- Author
-
Sue, Megan J, Lee, Edward W, Saab, Sammy, McWilliams, Justin P, Durazo, Francisco, El-Kabany, Mohamed, Kaldas, Fady, Busuttil, Ronald W, and Kee, Stephen T
- Subjects
Clinical Sciences - Abstract
OBJECTIVES:To investigate the safety profile and diagnostic efficacy of transjugular liver biopsy (TJLB), with a focus on patients with severe coagulopathies and with multiple biopsies. METHODS:Clinical, laboratory, and demographic information was collected on 1,321 TJLBs in 932 patients (mean age 43.5 ± 23.2 years) performed between January 2009 and May 2017 to determine the diagnostic success rate and incidence of both major and minor complications in the 3-day and 30-day period post-biopsies. These outcomes were also analyzed for severely coagulopathic patients and a subgroup of patients who underwent multiple biopsies. RESULTS:The overall success rate (diagnostic yield) of the TJLB procedure was 97.7% (1,291/1,321). Overall, the major and minor complication rates were 1.0% (13/1,321) and 9.5% (126/1,321), respectively. In patients with multiple biopsies, the overall complication rate was similar to the entire study cohort, which was 10.4% (57/550). Patients were also stratified according to the platelet counts of 0-50, 51-100, 101-200, 201-300 and >300 × 10 platelets/μL. The overall complication rates were 8.0% (10/124), 11.6% (36/310), 9.9% (54/547), 11.9% (28/235), and 14.3% (11/77), respectively, and these were not statistically significant from each other. Patients were also stratified by international normalized ratio into 0-1, 1.1-2, 2.1-3, and >3. The overall complication rates of these patients were 8.0% (19/237), 11.8% (113/954), 16.3% (7/43), and 0% (0/9), respectively, and were not statistically significant from each other. DISCUSSION:TJLB is a highly efficacious, well-tolerated and safe procedure. It can be safely performed multiple times in the same patient or in critically ill, severely coagulopathic patients with no significant increase in the rate of complication while maintaining an extremely favorable diagnostic yield.
- Published
- 2019
28. AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia
- Author
-
Najafian, Nilofar, Weber, Andrew T., Zuckerman, Jonathan E., Zhang, Sarah, Saab, Sammy, and Choi, Gina
- Published
- 2022
- Full Text
- View/download PDF
29. Post-COVID-19 Cholangiopathy: A Systematic Review
- Author
-
Yanny, Beshoy, Alkhero, Mohammed, Alani, Mohammed, Stenberg, Daniel, Saharan, Aryan, and Saab, Sammy
- Published
- 2022
- Full Text
- View/download PDF
30. Barriers for Liver Transplant in Patients with Alcohol-Related Hepatitis
- Author
-
Choi, Gina, Benhammou, Jihane N., Yum, Jung J., Saab, Elena G., Patel, Ankur P., Baird, Andrew J., Aguirre, Stephanie, Farmer, Douglas G., and Saab, Sammy
- Published
- 2022
- Full Text
- View/download PDF
31. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017–2019
- Author
-
Reau, Nancy, Sulkowski, Mark S., Thomas, Emmanuel, Sundaram, Vinay, Xu, Qingqing, Cheng, Wei-Han, Marx, Steven E., Hayes, Oscar A., Manthena, Shivaji R., Chirikov, Viktor, Dylla, Douglas E., Brooks, Hannah, Carabino, Jana M., and Saab, Sammy
- Published
- 2021
- Full Text
- View/download PDF
32. Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis
- Author
-
Aby, Elizabeth S., Pham, Nguyen V., Yum, Jung J., Dong, Tien S., Ghasham, Hussein, Bedier, Fatima, Malley, Claire, Schaenman, Joanna, and Saab, Sammy
- Published
- 2021
- Full Text
- View/download PDF
33. Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA Glomerulonephritis.
- Author
-
Hanna, Ramy, So, Naomi, Kaldas, Marian, Hou, Jean, Arman, Farid, Sangalang, Michelle, Yanny, Bishoy, Selamet, Umut, Saab, Sammy, Nobakht, Niloofar, and Rastogi, Anjay
- Subjects
Cryoglobulin antibodies ,Hepatitis C virus-associated glomerular disease ,Necrotizing crescentic p-ANCA glomerulonephritis ,Perinuclear anti-neutrophil cytoplasmic antibodies - Abstract
Hepatitis C (HCV) infection has a prevalence of 3 million infected individuals in the United States, according to recent Center for Disease Control reports, and can have various renal manifestations. Cryoglobulins, antibodies that precipitate at colder temperatures in vitro, are a relatively common cause of renal disease in HCV infection. The cryoglobulin proteins can form occlusive aggregates in small glomerular capillary lumina or deposit in other areas of the glomerulus, resulting in hypocomplementemia, proteinuria, hematuria, and renal injury. The typical biopsy pattern is that of membranoproliferative glomerulonephritis (MPGN). There are, however, other HCV-related patterns of glomerular injury. Anti-neutrophil cytoplasmic antibodies (ANCA) are known to exist in HCV-infected patients. In many reported cases, ANCA serologic testing may appear positive due to cross-reactivity of the immune assays; however, the biopsy findings do not support ANCA-associated crescentic glomerulonephritis (GN)/vasculitis as the primary cause of glomerular injury. There are rare reports of microscopic polyangiitis (MPA) p-ANCA vasculitis, in patients with HCV infection. In comparison with the MPGN pattern of cryoglobulinemic glomerular injury, biopsies from these HCV-infected patients with concomitant MPA revealed a crescentic GN, associated with normal serum complement levels. We present a case of HCV-associated glomerular disease with the surprising biopsy finding of necrotizing and crescentic p-ANCA GN, with a background, low-grade mesangial immune complex GN. Thus, p-ANCA disease should also be considered in HCV-infected patients, in addition to the more typical lesions of MPGN or cryoglobulinemic GN.
- Published
- 2018
34. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life
- Author
-
Patel, Arpan A, Walling, Anne M, Ricks-Oddie, Joni, May, Folasade P, Saab, Sammy, and Wenger, Neil
- Subjects
Digestive Diseases ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Management of diseases and conditions ,7.2 End of life care ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Cross-Sectional Studies ,End Stage Liver Disease ,Female ,Health Care Costs ,Humans ,Male ,Middle Aged ,Palliative Care ,Patient Acceptance of Health Care ,Young Adult ,NIS ,Death ,HCC ,Palliation ,Clinical Sciences ,Gastroenterology & Hepatology - Abstract
Background & aimsThere has been increased attention on ways to improve the quality of end-of-life care for patients with end-stage liver disease; however, there have been few reports of care experiences for patients during terminal hospitalizations. We analyzed data from a large national database to increase our understanding of palliative care for and health care utilization by patients with end-stage liver disease.MethodsWe performed a cross-sectional, observational study to examine terminal hospitalizations of adults with decompensated cirrhosis using data from the National Inpatient Sample from 2009 through 2013. We collected data on palliative care consultation and total hospital costs, and performed multivariate regression analyses to identify factors associated with palliative care consultation. We also investigated whether consultation was associated with lower costs.ResultsAmong hospitalized adults with terminal decompensated cirrhosis, 30.3% received palliative care; the mean cost per hospitalization was $48,551 ± $1142. Palliative care consultation increased annually, and was provided to 18.0% of patients in 2009 and to 36.6% of patients in 2013 (P < .05). The mean cost for the terminal hospitalization did not increase significantly ($47,969 in 2009 to $48,956 in 2013, P = .77). African Americans, Hispanics, Asians, and liver transplant candidates were less likely to receive palliative care, whereas care in large urban teaching hospitals was associated with a higher odds of receiving consultation. Palliative care was associated with lower procedure burden-after adjusting for other factors, palliative care was associated with a cost reduction of $10,062.ConclusionsPalliative care consultation for patients with end-stage liver disease increased from 2009 through 2013. Palliative care consultation during terminal hospitalizations is associated with lower costs and procedure burden. Future research should evaluate timing and effects of palliative care on quality of end-of-life care in this population.
- Published
- 2017
35. Hepatitis C Treatment Among Primary Care and Specialty Providers: A Single Center Study, 2015 to 2022
- Author
-
Scialli, Anna, primary, Saab, Sammy, additional, Salimian, Anabel, additional, Bhattacharya, Debika, additional, and Goodman-Meza, David, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy
- Author
-
Trieu, Harry, Patel, Arpan, Wells, Christine, Saab, Sammy, and Lee, Edward Wolfgang
- Published
- 2021
- Full Text
- View/download PDF
37. Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C.
- Author
-
Aby, Elizabeth, Jimenez, Melissa A, Grotts, Jonathan F, Agopian, Vatche, French, Samuel W, Busuttil, Ronald W, and Saab, Sammy
- Subjects
Biopsy ,Hepatitis C ,Liver transplantation - Abstract
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality. Liver biopsies are commonly used to identify recurrent HCV and determine the need for antiviral therapy. The introduction of direct-acting antiviral agents (DAAs) has changed the management of recurrent HCV infection. This study aimed to describe the role of liver biopsies in liver transplant recipients with HCV after the introduction of DAAs. Methods: A retrospective analysis was performed looking at the rate of liver biopsies post-liver transplantation for HCV. The analysis included 475 adult liver transplants for hepatitis C performed at the University of California, Los Angeles from January 1, 2006 to October 1, 2015. Patients were divided into two eras, pre- and post-introduction of DAAs on December 1, 2013. Results: In the era before the introduction of DAAs, the percentage of patients biopsied was significantly higher compared to the era after the introduction of DAAs (56.1% vs. 26.9%, p < 0.001). Conclusions: The introduction of DAAs has changed the management of liver biopsy following liver transplantation and the management of recurrent HCV. Given that DAAs are well tolerated and have high efficacy, liver biopsies are no longer routinely used to justify the use antiviral therapy following liver transplantation.
- Published
- 2017
38. Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers
- Author
-
Castrejón, Mariana, Chew, Kara W, Javanbakht, Marjan, Humphries, Romney, Saab, Sammy, and Klausner, Jeffrey D
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Clinical Research ,Substance Misuse ,Hepatitis - C ,Hepatitis ,Liver Disease ,Patient Safety ,Infectious Diseases ,Health Services ,Prevention ,Chronic Liver Disease and Cirrhosis ,Emerging Infectious Diseases ,Drug Abuse (NIDA only) ,Infection ,Good Health and Well Being ,baby boomers ,care cascade ,hepatitis C virus ,linkage to care ,screening ,Clinical sciences ,Medical microbiology - Abstract
BackgroundWe implemented and evaluated a large health system-wide hepatitis C virus (HCV) screening and linkage to care program for persons born between 1945 and 1965 ("baby boomers").MethodsAn electronic health record (EHR) clinical decision support (CDS) tool for HCV screening for baby boomers was introduced in August 2015 for patients seen in the outpatient University of California, Los Angeles healthcare system setting. An HCV care coordinator was introduced in January 2016 to facilitate linkage to HCV care. We compared HCV testing in the year prior (August 2014-July 2015) to the year after (August 2015-July 2016) implementation of the CDS tool. Among patients with reactive HCV antibody testing, we compared outcomes related to the care cascade including HCV ribonucleic acid (RNA) testing, HCV RNA positivity, and linkage to HCV specialty care.ResultsDuring the study period, 19606 participants were screened for HCV antibody. Hepatitis C virus antibody screening increased 145% (from 5676 patients tested to 13930 tested) after introduction of the CDS intervention. Screening increased across all demographic groups including age, sex, and race/ethnicity, with the greatest increases among those in the older age groups. The addition of an HCV care coordinator increased follow-up HCV RNA testing for HCV antibody positive patients from 83% to 95%. Ninety-four percent of HCV RNA positive patients were linked to care postimplementation.ConclusionsIntroduction of an EHR CDS tool and care coordination markedly increased the number of baby boomers screened for HCV, rates of follow-up HCV RNA testing, and linkage to specialty HCV care for patients with chronic HCV infection.
- Published
- 2017
39. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
- Author
-
Saab, Sammy, Rheem, Justin, Jimenez, Melissa A, Fong, Tiffany M, Mai, Michelle H, Kachadoorian, Caterina A, Esmailzadeh, Negin L, Bau, Sherona N, Kang, Susan, Ramirez, Samantha D, Grotts, Jonathan, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Han, Steven-Huy B, and Busuttil, Ronald W
- Subjects
Liver Disease ,Infectious Diseases ,Chronic Liver Disease and Cirrhosis ,Emerging Infectious Diseases ,Hepatitis ,Transplantation ,Clinical Trials and Supportive Activities ,Clinical Research ,Organ Transplantation ,Genetics ,Hepatitis - C ,Digestive Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Liver transplantation ,Immunosuppressant ,Hepatitis C ,Directacting agents ,Sustained viral response ,Direct-acting agents - Abstract
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality. Methods: We retrospectively evaluated the safety and efficacy of ledipasvir/sofosbuvir with and without ribavirin in LT recipients with recurrent genotype 1 hepatitis C. Results: Eighty-five LT recipients were treated for recurrent HCV with ledipasvir/sofosbuvirwith and without ribavirin for 12 or 24 weeks. The mean (± standard deviation [SD]) time from LT to treatment initiation was 68 (±71) months. The mean (± SD) age of the cohort was 63 (±8.6) years old. Most recipients were male (70%). Baseline alanine transaminase, total bilirubin, and HCV ribonucleic acid (RNA) values (± SD) were 76.8 (±126) mg/dL, 0.8 (±1.3) U/L, and 8,010,421.9 (±12,420,985) IU/mL, respectively. Five of 43 recipients who were treated with ribavirin required drug cessation due to side effects, with 4 of those being anemia complications. No recipient discontinued the ledipasvir/sofosbuvir. Eighty-one percent of recipients had undetectable viral levels at 4 weeks after starting therapy, and all recipients had complete viral suppression at the end of therapy. The sustained viral response at 12 weeks after completion of therapy was 94%. Conclusion : Ledipasvir and sofosbuvir with and without ribavirin therapy is an effective and well-tolerated interferon-free treatment for recurrent HCV infection after LT. Anemia is not uncommon in LT recipients receiving ribavirin.
- Published
- 2017
40. Incidence of abnormal liver biochemical tests in hyperthyroidism
- Author
-
Lin, Tiffany Y, Shekar, Anshula O, Li, Ning, Yeh, Michael W, Saab, Sammy, Wilson, Mark, and Leung, Angela M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Clinical Research ,Liver Disease ,Rare Diseases ,Adult ,Aged ,Female ,Humans ,Hyperthyroidism ,Incidence ,Liver Diseases ,Liver Function Tests ,Male ,Middle Aged ,Retrospective Studies ,Risk Factors ,Thyrotoxicosis ,Paediatrics and Reproductive Medicine ,Endocrinology & Metabolism ,Clinical sciences - Abstract
ObjectiveAbnormal serum liver function tests are common in patients with untreated thyrotoxicosis, even prior to the initiation of antithyroidal medications that may worsen the severity of the abnormal serum liver biochemistries. There is a wide range of the incidence of these abnormalities in the published literature. The aim of this study was to assess the risks factors and threshold of thyrotoxicosis severity for developing an abnormal liver biochemical test upon the diagnosis of new thyrotoxicosis.DesignSingle-institution retrospective cohort study.PatientsPatients of ≥18 years old receiving medical care at a large, academic, urban US medical centre between 2002-2016.MeasurementsInclusion criteria were a serum thyroid stimulating hormone (TSH) concentration of
- Published
- 2017
41. The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study
- Author
-
May, Folasade P, Rolston, Vineet S, Tapper, Elliot B, Lakshmanan, Ashwini, Saab, Sammy, and Sundaram, Vinay
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Alcoholism ,Alcohol Use and Health ,Digestive Diseases ,Substance Misuse ,Hepatitis ,Liver Disease ,Health Services ,Clinical Research ,Good Health and Well Being ,Adult ,Black or African American ,Cross-Sectional Studies ,Ethnicity ,Female ,Hepatitis ,Alcoholic ,Hispanic or Latino ,Hospital Costs ,Hospital Mortality ,Humans ,Length of Stay ,Male ,Middle Aged ,Patient Acceptance of Health Care ,United States ,White People ,Liver disease ,Nationwide inpatient sample ,Disparities ,Healthcare utilization ,Alcoholic hepatitis ,Public Health and Health Services ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
BackgroundAlcoholic Hepatitis (AH) is major source of alcohol-related mortality and health care expenditures in the United States. There is insufficient information regarding the role of race and ethnicity on healthcare utilization and outcomes for patients with AH. We aimed to determine whether there are racial/ethnic differences in resource utilization and inpatient mortality in patients hospitalized with AH.MethodsWe analyzed data from the Nationwide Inpatient Sample (NIS), years 2008-2011. We calculated demographic, clinical, and healthcare utilization characteristics by race. We then performed logistic regression and generalized linear modeling with gamma distribution (log link), respectively, to determine predictors of inpatient morality and total hospital costs (THC).ResultsWe identified 11,304 AH patients from 2008 to 2011. Mean age was 47.0 years, and 62.1 % were male, 61.9 % were white, 9.8 % were black, and 9.7 % were Hispanic. Mean LOS was 6.3 days and significantly longer in whites (6.5 d) than both blacks (5.4 d) and Hispanics (5.9 d). In adjusted models, inpatient mortality was lower for blacks than for whites (adj. OR = 0.50; 95 % CI = 0.32-0.78). THC was significantly higher for Hispanics than whites (fold increase = 1.25; 95 % CI = 1.01-1.49).ConclusionsWe identified differences in healthcare utilization and mortality by race/ethnicity. THC was significantly higher among Hispanics than for whites and blacks. We also demonstrated lower inpatient mortality in blacks compared to whites. These variations may implicate racial and ethnic differences in access to care, quality of care, severity of AH on presentation, or other factors.
- Published
- 2016
42. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist
- Author
-
Winters, Adam C., Bedier, Fatima, and Saab, Sammy
- Published
- 2020
- Full Text
- View/download PDF
43. Ascites : Ascites in Cirrhosis
- Author
-
Corson, Melissa, Najarian, Lisa M., Saab, Sammy, Cohen, Stanley Martin, editor, and Davitkov, Perica, editor
- Published
- 2019
- Full Text
- View/download PDF
44. Clinical Epidemiology of Chronic Liver Disease: Hepatocellular Carcinoma
- Author
-
Suraweera, Duminda, Konyn, Peter, Vu, Thomas, Saab, Sammy, Wong, Robert J., editor, and Gish, Robert G., editor
- Published
- 2019
- Full Text
- View/download PDF
45. Cardiovascular and metabolic disease in the liver transplant recipient
- Author
-
Kim, Nathan G., Sharma, Avneesh, and Saab, Sammy
- Published
- 2020
- Full Text
- View/download PDF
46. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt.
- Author
-
Lee, Edward Wolfgang, Kuei, Andrew, Saab, Sammy, Busuttil, Ronald W, Durazo, Francisco, Han, Steven-Huy, El-Kabany, Mohamed M, McWilliams, Justin P, and Kee, Stephen T
- Subjects
Humans ,Esophageal and Gastric Varices ,Hepatic Encephalopathy ,Hypertension ,Portal ,Respiratory Insufficiency ,Ascites ,Emergencies ,Gastrointestinal Hemorrhage ,Length of Stay ,Patient Transfer ,Portasystemic Shunt ,Transjugular Intrahepatic ,Hospital Mortality ,Multivariate Analysis ,Logistic Models ,Odds Ratio ,Risk Factors ,Retrospective Studies ,Adolescent ,Adult ,Aged ,Middle Aged ,Child ,Child ,Preschool ,Infant ,Infant ,Newborn ,United States ,Female ,Male ,Young Adult ,Acute Kidney Injury ,White People ,Black or African American ,Health Cost and Utilization Project ,Inpatient ,Mortality ,National Inpatient Sample database ,Transjugular intrahepatic portosystemic shunt ,Clinical Research ,Health Services ,Good Health and Well Being ,African Americans ,Whites ,Clinical Sciences ,Gastroenterology & Hepatology - Abstract
AimTo evaluate and validate the national trends and predictors of in-patient mortality of transjugular intrahepatic portosystemic shunt (TIPS) in 15 years.MethodsUsing the National Inpatient Sample which is a part of Health Cost and Utilization Project, we identified a discharge-weighted national estimate of 83884 TIPS procedures performed in the United States from 1998 to 2012 using international classification of diseases-9 procedural code 39.1. The demographic, hospital and co-morbility data were analyzed using a multivariant analysis. Using multi-nominal logistic regression analysis, we determined predictive factors related to increases in-hospital mortality. Comorbidity measures are in accordance to the Comorbidity Software designed by the Agency for Healthcare Research and Quality.ResultsOverall, 12.3% of patients died during hospitalization with downward trend in-hospital mortality with the mean length of stay of 10.8 ± 13.1 d. Notable, African American patients (OR = 1.809 vs Caucasian patients, P < 0.001), transferred patients (OR = 1.347 vs non-transferred, P < 0.001), emergency admissions (OR = 3.032 vs elective cases, P < 0.001), patients in the Northeast region (OR = 1.449 vs West, P < 0.001) had significantly higher odds of in-hospital mortality. Number of diagnoses and number of procedures showed positive correlations with in-hospital death (OR = 1.249 per one increase in number of procedures). Patients diagnosed with acute respiratory failure (OR = 8.246), acute kidney failure (OR = 4.359), hepatic encephalopathy (OR = 2.217) and esophageal variceal bleeding (OR = 2.187) were at considerably higher odds of in-hospital death compared with ascites (OR = 0.136, P < 0.001). Comorbidity measures with the highest odds of in-hospital death were fluid and electrolyte disorders (OR = 2.823), coagulopathy (OR = 2.016), and lymphoma (OR = 1.842).ConclusionThe overall mortality of the TIPS procedure is steadily decreasing, though the length of stay has remained relatively constant. Specific patient ethnicity, location, transfer status, primary diagnosis and comorbidities correlate with increased odds of TIPS in-hospital death.
- Published
- 2016
47. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
- Author
-
Lee, Edward Wolfgang, Alanis, Lourdes, Cho, Sung-Ki, and Saab, Sammy
- Subjects
Humans ,Carcinoma ,Hepatocellular ,Liver Neoplasms ,Jaundice ,Yttrium Radioisotopes ,Drug Carriers ,Radiopharmaceuticals ,Magnetic Resonance Imaging ,Brachytherapy ,Microspheres ,Hepatocellular carcinoma ,Radioembolization ,Selective internal radiation therapy ,Yttrium 90 ,Carcinoma ,Hepatocellular ,Clinical Sciences ,Other Medical and Health Sciences ,Nuclear Medicine & Medical Imaging - Abstract
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.
- Published
- 2016
48. Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use
- Author
-
Saab, Sammy, Rheem, Justin, Jimenez, Melissa, Bau, Sherona, Choi, Gina, Durazo, Francisco, Kabany, Mohammed El, Han, Steven, Farid, Alexander, Jamal, Naadir, Grotts, Jonathan, Elashoff, David, and Busuttil, Ronald W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Liver Disease ,Transplantation ,Chronic Liver Disease and Cirrhosis ,Emerging Infectious Diseases ,Hepatitis ,Infectious Diseases ,Hepatitis - C ,Organ Transplantation ,Digestive Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Liver transplantation ,Immunosuppressant ,Hepatitis C ,Direct acting agents - Abstract
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients. The aim of the study was to assess immunosuppression needs after achieving a sustained viral response (SVR).MethodsWe compared immunosuppression needs before and after achieving a SVR in adult LT recipients treated for recurrent HCV infection with all-oral direct acting agents.ResultsWe identified 52 liver LT treated recipients who achieved a SVR. The median (25th and 75th percentile interquartile range [IQR]) age was 62 years (57.75, 65). Most recipients received tacrolimus (TAC) for their immunosuppressant regimen. After achieving SVR, there was no statistically significant difference in daily dose of TAC unadjusted per weight (p > 0.05). However, there was a statistically significant decrease in daily dose of TAC adjusted per weight, serum levels of TAC, and the product of glomerular filtration rate and TAC. No statistically significant differences in cyclosporine unadjusted/adjusted per weight daily dose or serum levels were noted.ConclusionsImmunosuppression needs were increased for those patients treated with TAC but not cyclosporine. LT recipients prescribed TAC require close monitoring after treatment completion to avoid potential risk of acute rejection.
- Published
- 2016
49. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C
- Author
-
Lu, Nu T, Crespi, Catherine M, Liu, Natalie M, Vu, James Q, Ahmadieh, Yasaman, Wu, Sheng, Lin, Sherry, McClune, Amy, Durazo, Francisco, Saab, Sammy, Han, Steven, Neiman, David C, Beaven, Simon, and French, Samuel W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Emerging Infectious Diseases ,Hepatitis - C ,Complementary and Integrative Health ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Hepatitis ,Clinical Research ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Digestive Diseases ,HIV/AIDS ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Adult ,Aged ,Alanine Transaminase ,Antiviral Agents ,Aspartate Aminotransferases ,Dose-Response Relationship ,Drug ,Female ,Hepacivirus ,Hepatitis C ,Chronic ,Humans ,Male ,Middle Aged ,Quercetin ,Viral Load ,bioflavonoids ,dose escalation ,hepatitis C ,phase I ,phytomedicine ,quercetin ,Chemical Sciences ,Biological Sciences ,Medical and Health Sciences ,Medicinal & Biomolecular Chemistry ,Biomedical and clinical sciences ,Chemical sciences ,Health sciences - Abstract
The hepatitis C virus (HCV) infects more than 180 million people worldwide, with long-term consequences including liver failure and hepatocellular carcinoma. Quercetin bioflavonoids can decrease HCV production in tissue culture, in part through inhibition of heat shock proteins. If quercetin demonstrates safety and antiviral activity in patients, then it could be developed into an inexpensive HCV treatment for third world countries or other affected populations that lack financial means to cover the cost of mainstream antivirals. A phase 1 dose escalation study was performed to evaluate the safety of quercetin in 30 untreated patients with chronic HCV infection and to preliminarily characterize quercetin's potential in suppressing viral load and/or liver injury. Quercetin displayed safety in all trial participants. Additionally, 8 patients showed a "clinically meaningful" 0.41-log viral load decrease. There was a positive correlation (r = 0.41, p = 0.03) indicating a tendency for HCV decrease in patients with a lower ratio of plasma quercetin relative to dose. No significant changes in aspartate transaminase and alanine transaminase were detected. In conclusion, quercetin exhibited safety (up to 5 g daily) and there was a potential for antiviral activity in some hepatitis C patients.
- Published
- 2016
50. Commentary on New Fatty Liver Nomenclature
- Author
-
Shetty, Akshay, primary and Saab, Sammy, additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.